



**Thursday June 13, 2024**

**09.15-09.50 Registration & Coffee/Tea**

**09.50-10.00 Welcome**

Please Note; Selected abstract-presenters have exactly 15 minutes to present their data, including a few minutes discussion. Please make sure your presentation is on the computer before the session starts.

**10.00-11.15 Oral presentation Session 1 (5 speakers)**

Session chair: Diede van Ens

***PI3K - AKT1 - mTOR activity and BTN3A1 phosphorylation are required for early cancer immune surveillance via Vγ9Vδ2TCR T cell***

Peter Brazda, UMC Utrecht

***Differential capacity of vaccine adjuvant to stimulate liver tissue-resident memory T cells***

Aru Z. Wang, Amsterdam UMC

***The immunoregulatory role of Head and Neck Squamous Cell Carcinoma-derived CAFs in a radiotherapeutic setting***

Kris Raaijmakers, Radboudumc

***CD4+ T-cells produce IFN- $\gamma$  to license cDC1 for induction of cytotoxic T-cell activity in human tumors***

Xin Lei, LUMC

***Next generation T cell receptors equipped with ICOS mediate durable anti-tumor activity***

Alexandre Marraffa, Erasmus MC

**11.15-11.40 Coffee/Tea Break**

**11:40-12:00 Valorization in practice, invited speaker**

**Prof. Sjoerd van der Burg, PhD**

*Medical Oncology, Onco Institute, LUMC, Leiden, Netherlands*

**“TEIPP targeting for immune escaped cancers, from bench to bed-side”**

**12.00-13.00 Oral presentation Session 2 (4 speakers)**

Session Chair: Simone Kleinendorst

***CRISPR-Cas9-mediated knockout of TGF- $\beta$ 2 improves HPC-NK-cell efficacy against target cells in vitro and renders them insensitive to TGF- $\beta$ 1***

Iris Hagemans, Radboudumc

***Intra-tumor neopeptide vaccine together with systemic neopeptide vaccine inhibits tumor growth in a mouse model***

Kou Hioki, Erasmus MC

***Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products***

Suzanne Castenmiller, Sanquin

***The properties of mesenchymal stem cells in the tumor niche direct the outcome of engineered T cell therapy***

Angelo Meringa, UMC Utrecht

**13.00-14.00 Lunch**

**14.00-15.00 Oral presentation Session 3 (4 speakers)**

Session 3: Tetje van der Sluis

***PROTACs as a novel immunotherapeutic tool to boost CTL responses against cancer***

Brett Hos, Erasmus MC

***Phase I trial investigating neo-adjuvant DURvalumab administered IntraTumorally (DURVIT) in early-stage cervical cancer: safety, toxicity and immunological effects***

Marije Strikwerda, Amsterdam UMC

***Targeting dysregulated metabolism of tumors using affinity enhanced  $\gamma$ 9 $\delta$ 2TCR engineered T cells and bispecific T cell engagers***

Mara Nicolassen, UMC Utrecht

***Cell cycle inhibition kickstarts CD8+ T cell proliferation by changing metabolism and IL-2 signalling***

Floortje van Haften, LUMC

**15.00-15.15 Coffee/Tea Break**

**15.15-16.15 Oral presentation Session 4 (4 speakers)**

Session chair: Xiurong Ke

***Exploiting bioorthogonal chemistry to study antigen presentation***

Amy Kessler, Erasmus MC

**Exploring the therapeutic potential of mucosal-associated invariant T (MAIT) cells: optimized expansion and activation of MAIT cells in gastric cancer**

Beatriz Ferreira Costa, Amsterdam UMC

**Glutaminyl cyclase can modulate therapeutic antibody binding**

Anneloes van der Plas-van Duijn, LUMC

**Leukotriene B4 acts via interleukin-8 to attract and activate neutrophils to induce IgA-mediated antibody dependent cellular cytotoxicity**

Patricia Olofsen, UMC Utrecht

**16:15 – 17.45 Laptop sessions**

Please note: Each laptop session consists of 3 rounds of 8 min (5 min laptop presentations followed by 3 minutes of discussion). Laptop presenters, please bring a fully charged laptop with your presentation to the session.

**16:15-16:45 Laptop Session 1**

**Table 1: Accelerating clinical translation of Advanced Therapeutic Medicinal Products: the significance of a good manufacturing practice simulation facility**

Aiko Ballardini, UMC Utrecht

**Table 2: Oncolytic alphavirus replicons mediated recruitment and activation of T cells**

Darshak Bhatt, UMCG

**Table 3: SF3B1 mutations affect NK cell function in myeloid neoplasms**

Mylene Gerritsen, Radboudumc

**Table 4: Methyltransferase DOT1L is important for the development of plasmacytoid dendritic cells in murine bone marrow**

Rianne Bouma, Amsterdam UMC

**Table 5: Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model**

Rui M.L. Coelho, Erasmus MC

**Table 6: The role of CD56bright and CD56dim NK cells in cellular immunotherapy; are CD56bright cells just precursors or rapid responders?**

Els van Hees, LUMC

**Table 7: Hematopoietic stem cell-derived NK cells engineered with chimeric antigen receptors as off-the-shelf cancer therapy**

Laura Hooijmaijers, Radboudumc

**Table 8: Co-evolution of macrophages and fibroblasts in an in vitro model of colorectal cancer**

Eline Janssen, Radboudumc

***Table 9: T-cell receptors for hematopoietic-restricted minor histocompatibility antigens to treat acute myeloid leukemia after allogeneic stem cell transplantation***

Georgia Koutsoumpli, LUMC

***Table 10: Identification and characterization of tumor-reactive CD8 and CD4 T cells in hepatocellular carcinoma***

Luc Magré, Erasmus MC

***Table 11: CAR-mediated target recognition limits TCR-mediated target recognition by TCR- and CAR-dual-receptor-edited T cells***

Teuntje Poortvliet, LUMC

***Table 12: Comparison of different gangliosides/ $\alpha$ -Galactosylceramide containing liposomes for their capacity to promote adaptive immune responses in spleen and liver***

Negisa Seyed Toutounchi, Amsterdam UMC

**16:45-17:15                  Laptop Session 2**

***Table 1: CRISPR-Cas9 RNP knockout of ZEB2 in human CD34+ stem cells results in increased cDC1 differentiation***

Diede van Ens, Radboudumc

***Table 2: CRISPR-cas9 gene engineering for targeted integration of the T cell receptor***

Cilia Pothast, LUMC

***Table 3: SONATA: Integration of Whole-Genome Sequencing Profiles and Immune Status in Cancer - targets and immune contexture in melanoma and PDAC***

Sophie Veenstra, Amsterdam UMC

***Table 4: Ex vivo immunopharmacological bio-assay measuring the effect of immune checkpoint inhibition in healthy volunteers as well as cancer and sepsis***

Judith Verdonk, Radboudumc

***Table 5: Assessment of the value of tumor CD169+ and CD169- myeloid cells for prognosis and treatment of human hepatocellular carcinoma (HCC)***

Patrick Boor, Erasmus MC

***Table 6: Immune signature for HER2-low breast cancer***

Xi Zhang, LUMC

***Table 7: Tumor immune escape: TAM-induced T cell exhaustion and immunosuppression***

Eleni Grosu, Radboudumc

***Table 8: Multiplex immunohistochemistry to study the role of JAK3 and TEC family kinases in vitiligo and skin cancer***

Emma Holtappels, Amsterdam UMC

**Table 9: Redirecting pre-existing anti-CMV immunity to selectively target HER2-positive breast cancer cells**

Xiurong Ke, UMCG

**Table 10: Combining Tumour Infiltrating Lymphocytes, checkpoint inhibition and IFN $\alpha$  induces clinical benefit in metastatic melanoma patients refractory to standard therapies**

Anique Verpoorte, LUMC

**Table 11: Enhancing neutrophil activity against neuroblastoma using a combination of CD47 blockade and IgA immunotherapy**

Ida van der Peet, UMC Utrecht

**17:15-17:45 Laptop Session 3**

**Table 1: A Novel Cancer-Selective hIFN $\alpha$  Immunocytokine Inducing Dual Anticancer Activity**

Douwe Samplonius, UMCG

**Table 2: Vaccination escaped tumors in mice are re-sensitized to therapeutic vaccination with cisplatin-induced CD8 T cell activation**

Pieter Schol, LUMC

**Table 3: Exploring the effect of supervised exercise during chemotherapy on immune cell function and tumour infiltration in patients with breast cancer**

Anna Ubink, Radboudumc

**Table 4: Monitoring the immune microenvironment (MIMIC) of pediatric high grade brain malignancies: insights into T-cell dynamics and checkpoint expression**

Joyce Meesters-Ensing, UMC Utrecht

**Table 5: Unconventional neo-antigens mediated APOBEC3 mutagenesis in breast cancer**

Hamdy Warda, Erasmus MC

**Table 6: Assessment of adoptive T cell therapy - using TILs - as a therapeutic option for neuroblastoma**

Leyma Wardak, Sanquin

**Table 7: The TGF- $\beta$ /GARP axis in immune suppression of head and neck cancer**

Loth Webbink, Amsterdam UMC

**Table 8: BOB1-TCR gene therapy for the treatment of multiple myeloma**

Johannes Wellershof, LUMC

**Table 9: A novel TCR-like antibody-based approach for redirecting pre-existing antiviral immunity to selectively kill cancer cells**

Anne van Wijngaarden, UMCG

**Table 10: Beyond classical antigen presentation: a spatial and genomic analysis of HLA expression in colon cancer immune evasion and patient outcomes**

Hehuan Zhu, LUMC

**Table 11: Unravelling radiobiological and immunological mechanisms driving effective CAIX-TRT and ICI combination therapy**

Simone Kleinendorst, Radboudumc

**17.45-18.00**            **Break**

**18.00-19.00**            **Keynote speaker**

**Prof. Aurélien Marabelle, MD, PhD**

*Immunotherapy Translational Research Lab (LRTI), INSERM, Paris, France*

**“Primary Resistance to Cancer Immunotherapy:  
Lessons Learned from Patients Treated”**

**19.00-20.30**            **Dinner**

**20.30-21.30**            **Keynote speaker**

**Dr. Jennifer Guerreiro, PhD**

*Breast Tumor Immunology Laboratory, Dana-Farber Cancer Institute, Boston, USA*

**“Leveraging the complexities of tumor associated macrophages  
for effective anti-cancer therapy”**

**21.30-00.00**            **Networking party**



# DTIM KWF

Dutch Tumor Immunology Meeting

## Friday June 14, 2024

**09.00-10.30**

**Oral presentation Session 5 (6 speakers)**

Session chair: Lenneke Cornelissen

***A novel CD117xCD3-T cell engager for the elimination of leukemia-initiating stem cells***  
Giada dal Collo, Erasmus MC

***Efficacy of  $\alpha\beta$ T cell based immunotherapies relies on CCR5 expression in both CD4+ and CD8+  $\alpha\beta$ T cells***  
Caroline Schwenzel, UMC Utrecht

***Ex vivo tumor testing to assess patient-specific sensitivity to immunomodulatory therapies***  
Lieke Ceton, Vitroscan

***ATM and ATR inhibition increases radiosensitivity and may improve immunogenicity of prostate cancer***  
Nina van Campen, Radboudumc

***The therapeutic potential of V $\delta$ 1+  $\gamma\delta$  T-cells in primary colorectal cancer of microsatellite stable patients***  
Lucrezia Gatti, UMC Utrecht

***Development of tissue resident memory T cells in pancreatic cancer***  
Hester Heimans, LUMC

**10.30-11.00**

***Coffee/Tea Break***

**11.00-12.00**

**Valorization Workshop**

**Drs. Timo Smets, MSc**

*Valorisatie bureau Amsterdam UMC, Amsterdam, Netherlands*

**“Valorization: The road from lab findings to patient benefits”**

**12.00-12.30**

**Valorization in practice, invited speaker**

**Dr. Thomas Boltje**

*Co-founder Synvenio and Glycotherapeutics, Radboud UMC, Nijmegen, Netherlands*

**“Glycotherapeutics: Targeting glycans as a novel cancer therapy”**

**12:30-13:30**            **Lunch**

**13.30-14.10**            **Oral presentation Session 6 (2 speakers, 20 min each)**

Session chair: Marij Welters

***Contribution of Cancer-Associated Fibroblast subtypes to composition and stiffness of the extracellular matrix in the tumour stroma***

Alessandra Cambi, Radboudumc

***IgA antibody therapy induces memory immune response against cancer***

Maria Tsioumpekou, UMC Utrecht

**14.10-15.10**            **Keynote speaker 3**

**Dr. Anne Rios, PhD**

*Princess Máxima Center for Pediatric Oncology, Oncode Institute, UMCU, Utrecht, Netherlands*

**“Organoids; cancer immunity models in motion”**

**15.10-15.30**            **KWF questionnaire, AIO Award Ceremony & Closure**

**Thanks to our sponsors for supporting this meeting:**

